TRCT
INDV icon

Tower Research Capital (TRC)’s Indivior Pharmaceuticals INDV Stock Holding History

Tower Research Capital (TRC)’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$289K Buy
7,032
+6,037
+607% +$219K 0.01% 1420
2026
Q1 		$30.3K Sell
995
-398
-29% -$13.1K ﹤0.01% 3158
2025
Q4 		$50K Sell
1,393
-1,811
-57% -$55.3K ﹤0.01% 2413
2025
Q3 		$77.2K Sell
3,204
-7,363
-70% -$154K ﹤0.01% 2197
2025
Q2 		$156K Buy
10,567
+9,456
+851% +$110K ﹤0.01% 2018
2025
Q1 		$10.6K Buy
1,111
+94
+9% +$988 ﹤0.01% 3623
2024
Q4 		$12.6K Buy
1,017
+712
+233% +$7.32K ﹤0.01% 3599
2024
Q3 		$2.97K Sell
305
-211
-41% -$2.47K ﹤0.01% 4915
2024
Q2 		$8.32K Sell
516
-3,022
-85% -$54.5K ﹤0.01% 4367
2024
Q1 		$75.8K Buy
+3,538
New +$66.5K ﹤0.01% 1994

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tower Research Capital (TRC)'s INDV Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Indivior Pharmaceuticals (INDV) stake by 607% in Q2 2026, buying an estimated $219K and bringing the position to 7,032 shares worth $289K. The position accounts for 0.01% of the portfolio, ranked #1420.

Tower Research Capital (TRC) first reported a position in INDV in Q1 2024 and has held it in 10 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Tower Research Capital (TRC) held 7,032 shares of Indivior Pharmaceuticals worth $289K as of Q2 2026.
  • Tower Research Capital (TRC) bought 6,037 Indivior Pharmaceuticals shares in Q2 2026, an estimated $219K.
  • Indivior Pharmaceuticals made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1420 holding.
  • Tower Research Capital (TRC) first reported a position in Indivior Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.